c-car011
Cell therapyexperimental
Clinical trial activity
5 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2016 (NCT02976857)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- B-lymphocyte antigen CD19Immunity, passive
CD19 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- c-car011
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03327285 | N/A | Oct 15, 2018 | Cellular Biomedicine Group Ltd., Peking University |
| NCT03299738 | Phase 1 | Dec 31, 2017 | Cellular Biomedicine Group Ltd., Tianjin Medical University |
| NCT03154775 | Phase 1 | May 3, 2017 | Cellular Biomedicine Group Ltd., Huazhong University of Science and Technology |
| NCT03018093 | Phase 1 | Jan 1, 2017 | Cellular Biomedicine Group Ltd., People's Liberation Army of China |
| NCT02976857 | Phase 1 | Dec 1, 2016 | Cellular Biomedicine Group Ltd., Nanjing Medical University |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cellular Biomedicine Group Ltd. | For profit | 5 | 4 | 2 | 2016 |
| Huazhong University of Science and Technology | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Nanjing Medical University | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Peking University | Academic/Hospital | 1 | 1 | 1 | 2018 |
| People's Liberation Army of China | Government | 1 | 0 | 1 | 2017 |
| Tianjin Medical University | Academic/Hospital | 1 | 0 | 1 | 2017 |
6 organizations
Page 1 / 1